{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:07:30Z","timestamp":1792278450839,"version":"4.4.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T00:00:00Z","timestamp":1538524800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["Lecture fee"],"award-info":[{"award-number":["Lecture fee"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["Lecture fees"],"award-info":[{"award-number":["Lecture fees"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","award":["Lecture fees"],"award-info":[{"award-number":["Lecture fees"]}],"id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","award":["Lecture fees"],"award-info":[{"award-number":["Lecture fees"]}],"id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","award":["Lecture fees"],"award-info":[{"award-number":["Lecture fees"]}],"id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","award":["Grant"],"award-info":[{"award-number":["Grant"]}],"id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","award":["Lecture fees and\/or consulting fees"],"award-info":[{"award-number":["Lecture fees and\/or consulting fees"]}],"id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","award":["Lecture fees"],"award-info":[{"award-number":["Lecture fees"]}],"id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","award":["Grant"],"award-info":[{"award-number":["Grant"]}],"id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","award":["Lecture fees"],"award-info":[{"award-number":["Lecture fees"]}],"id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010793","name":"Pfizer Japan","doi-asserted-by":"publisher","award":["Grant"],"award-info":[{"award-number":["Grant"]}],"id":[{"id":"10.13039\/100010793","id-type":"DOI","asserted-by":"publisher"}]},{"name":"KYORIN Pharmaceutical Co., Ltd.","award":["Lecture fees"],"award-info":[{"award-number":["Lecture fees"]}]},{"name":"Mylan Inc.","award":["Lecture fees"],"award-info":[{"award-number":["Lecture fees"]}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","award":["Lecture fees"],"award-info":[{"award-number":["Lecture fees"]}],"id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005612","name":"Shionogi","doi-asserted-by":"publisher","award":["Consulting fees"],"award-info":[{"award-number":["Consulting fees"]}],"id":[{"id":"10.13039\/501100005612","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma","doi-asserted-by":"publisher","award":["Lecture fees"],"award-info":[{"award-number":["Lecture fees"]}],"id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004169","name":"Meiji Seika Pharma","doi-asserted-by":"publisher","award":["Lecture fees and\/or consulting fees"],"award-info":[{"award-number":["Lecture fees and\/or consulting fees"]}],"id":[{"id":"10.13039\/501100004169","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","award":["Grant"],"award-info":[{"award-number":["Grant"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","award":["Lecture fees and\/or consulting fees"],"award-info":[{"award-number":["Lecture fees and\/or consulting fees"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Sanwa Kagaku Kenkyusho Co., Ltd","award":["Lecture fees and\/or consulting fees"],"award-info":[{"award-number":["Lecture fees and\/or consulting fees"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00467-018-4099-8","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T01:28:45Z","timestamp":1538530125000},"page":"837-846","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Lisinopril versus lisinopril and losartan for mild childhood IgA nephropathy: a randomized controlled trial (JSKDC01 study)"],"prefix":"10.1007","volume":"34","author":[{"name":"for the Japanese Study Group of Kidney Disease in Children (JSKDC)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Shima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8681-9129","authenticated-orcid":false,"given":"Koichi","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayumi","family":"Sako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Saito-Oba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Hamasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Hataya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Kamei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ishikura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kaito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryojiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kandai","family":"Nozu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidefumi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumoto","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norishige","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,3]]},"reference":[{"key":"4099_CR1","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1056\/NEJMra020109","volume":"347","author":"JV Donadio","year":"2002","unstructured":"Donadio JV, Grande JP (2002) IgA nephropathy. N Engl J Med 347:738\u2013748","journal-title":"N Engl J Med"},{"key":"4099_CR2","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1111\/j.1523-1755.2004.00437.x","volume":"65","author":"E Alexopoulos","year":"2004","unstructured":"Alexopoulos E (2004) Treatment of primary IgA nephropathy. Kidney Int 65:341\u2013355","journal-title":"Kidney Int"},{"key":"4099_CR3","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1007\/s00467-007-0726-5","volume":"23","author":"N Yata","year":"2008","unstructured":"Yata N, Nakanishi K, Shima Y, Togawa H, Obana M, Sako M, Nozu K, Tanaka R, Iijima K, Yoshikawa N (2008) Improved renal survival in Japanese children with IgA nephropathy. Pediatr Nephrol 23:905\u2013912","journal-title":"Pediatr Nephrol"},{"key":"4099_CR4","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0002-9343(01)00659-3","volume":"110","author":"CC Szeto","year":"2001","unstructured":"Szeto CC, Lai FM, To KF, Wong TY, Chow KM, Choi PC, Lui SF, Li PK (2001) The natural history of immunoglobulin a nephropathy among patients with hematuria and minimal proteinuria. Am J Med 110:434\u2013437","journal-title":"Am J Med"},{"key":"4099_CR5","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1681\/ASN.2006040347","volume":"18","author":"R Coppo","year":"2007","unstructured":"Coppo R, Peruzzi L, Amore A, Piccoli A, Cochat P, Stone R, Kirschstein M, Linn\u00e9 T (2007) IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgA nephropathy and moderate proteinuria. J Am Soc Nephrol 18:1880\u20131888","journal-title":"J Am Soc Nephrol"},{"key":"4099_CR6","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.ajkd.2006.01.017","volume":"47","author":"PK Li","year":"2006","unstructured":"Li PK, Leung CB, Chow KM, Cheng YL, Fung SK, Mak SK, Tang AW, Wong TY, Yung CY, Yung JC, Yu AW, Szeto CC, HKVIN Study Group (2006) Hong Kong study using valsartan in IgA nephropathy (HKVIN): a double-blind, randomized, placebo-controlled study. Am J Kidney Dis 47:751\u2013760","journal-title":"Am J Kidney Dis"},{"key":"4099_CR7","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1097\/01.ASN.0000068460.37369.DC","volume":"14","author":"M Praga","year":"2003","unstructured":"Praga M, Guti\u00e9rrez E, Gonz\u00e1lez E, Morales E, Hern\u00e1ndez E (2003) Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol 14:1578\u20131583","journal-title":"J Am Soc Nephrol"},{"key":"4099_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1053\/ajkd.2001.25176","volume":"38","author":"D Russo","year":"2001","unstructured":"Russo D, Minutolo R, Pisani A, Esposito R, Signoriello G, Andreucci M, Balletta MM (2001) Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 38:18\u201325","journal-title":"Am J Kidney Dis"},{"key":"4099_CR9","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1291\/hypres.27.963","volume":"27","author":"Y Horita","year":"2004","unstructured":"Horita Y, Tadokoro M, Taura K, Suyama N, Taguchi T, Miyazaki M, Kohno S (2004) Low-dose combination therapy with temocapril and losartan reduces proteinuria in normotensive patients with immunoglobulin a nephropathy. Hypertens Res 27:963\u2013970","journal-title":"Hypertens Res"},{"key":"4099_CR10","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00467-008-1006-8","volume":"24","author":"K Nakanishi","year":"2009","unstructured":"Nakanishi K, Iijima K, Ishikura K, Hataya H, Awazu M, Sako M, Honda M, Yoshikawa N, Japanese Pediatric IgA Nephropathy treatment study group (2009) Efficacy and safety of lisinopril for mild childhood IgA nephropathy: a pilot study. Pediatr Nephrol 24:845\u2013849","journal-title":"Pediatr Nephrol"},{"key":"4099_CR11","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/S0022-3476(87)80547-4","volume":"110","author":"N Yoshikawa","year":"1987","unstructured":"Yoshikawa N, Ito H, Yoshihara S, Nakahara C, Yoshiya K, Hasegawa O, Matsuo T (1987) Clinical course of IgA nephropathy in children. J Pediatr 110:555\u2013560","journal-title":"J Pediatr"},{"key":"4099_CR12","first-page":"1375","volume":"69","author":"R Simon","year":"1985","unstructured":"Simon R, Wittes RE, Ellenberg SS (1985) Randomized phase II clinical trials. Cancer Treat Rep 69:1375\u20131381","journal-title":"Cancer Treat Rep"},{"key":"4099_CR13","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1002\/sim.704","volume":"20","author":"DJ Sargent","year":"2001","unstructured":"Sargent DJ, Goldberg RM (2001) A flexible design for multiple armed screening trials. Stat Med 20:1051\u20131060","journal-title":"Stat Med"},{"key":"4099_CR14","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1542\/peds.105.6.1242","volume":"105","author":"RJ Hogg","year":"2000","unstructured":"Hogg RJ, Portman RJ, Milliner D, Lemley KV, Eddy A, Ingelfinger J (2000) Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and elimination (PARADE). Pediatrics 105:1242\u20131249","journal-title":"Pediatrics"},{"key":"4099_CR15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1080\/08860220701260511","volume":"29","author":"Y Horita","year":"2007","unstructured":"Horita Y, Tadokoro M, Taura K, Ashida R, Hiu M, Taguchi T, Furusu A, Kohno S (2007) Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy. Ren Fail 29:441\u2013446","journal-title":"Ren Fail"},{"key":"4099_CR16","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1097\/01.ASN.0000092789.67966.5C","volume":"14","author":"N Lods","year":"2003","unstructured":"Lods N, Ferrari P, Frey FJ, Kappeler A, Berthier C, Vogt B, Marti HP (2003) Angiotensin-converting enzyme inhibition but not angiotensin II receptor blockade regulates matrix metalloproteinase activity in patients with glomerulonephritis. J Am Soc Nephrol 14:2861\u20132872","journal-title":"J Am Soc Nephrol"},{"key":"4099_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5414\/CNP64035","volume":"64","author":"Y Yang","year":"2005","unstructured":"Yang Y, Ohta K, Shimizu M, Nakai A, Kasahara Y, Yachie A, Koizumi S (2005) Treatment with low-dose angiotensin-converting enzyme inhibitor (ACEI) plus angiotensin II receptor blocker (ARB) in pediatric patients with IgA nephropathy. Clin Nephrol 64:35\u201340","journal-title":"Clin Nephrol"},{"key":"4099_CR18","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/j.1742-1241.2012.02970.x","volume":"66","author":"J Cheng","year":"2012","unstructured":"Cheng J, Zhang X, Tian J, Li Q, Chen J (2012) Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis. Int J Clin Pract 66:917\u2013923","journal-title":"Int J Clin Pract"},{"key":"4099_CR19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.semnephrol.2003.11.002","volume":"24","author":"P Ruggenenti","year":"2004","unstructured":"Ruggenenti P (2004) Angiotensin-converting enzyme inhibition and angiotensin II antagonism in nondiabetic chronic nephropathies. Semin Nephrol 24:158\u2013167","journal-title":"Semin Nephrol"},{"key":"4099_CR20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1053\/snep.2001.26793","volume":"21","author":"L Ma","year":"2001","unstructured":"Ma L, Fogo A (2001) Role of angiotensin II in glomerular injury. Semin Nephrol 21:544\u2013553","journal-title":"Semin Nephrol"},{"key":"4099_CR21","first-page":"431","volume":"17","author":"HN Ibrahim","year":"1997","unstructured":"Ibrahim HN, Rosenberg ME, Hostetter TH (1997) Role of the renin-angiotensin-aldosterone system in the progression of renal disease: a critical review. Semin Nephrol 17:431\u2013440","journal-title":"Semin Nephrol"},{"key":"4099_CR22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1056\/NEJM199604113341502","volume":"334","author":"G Maschio","year":"1996","unstructured":"Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P, The Angitensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 334:939\u2013945","journal-title":"N Engl J Med"},{"key":"4099_CR23","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1172\/JCI113590","volume":"82","author":"A Fogo","year":"1988","unstructured":"Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I (1988) Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 82:322\u2013330","journal-title":"J Clin Invest"},{"key":"4099_CR24","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/hc4101.096153","volume":"104","author":"AC Schoolwerth","year":"2001","unstructured":"Schoolwerth AC, Sica DA, Ballermann BJ, Wilcox CS, Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association (2001) Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation 104:1985\u20131991","journal-title":"Circulation"},{"key":"4099_CR25","doi-asserted-by":"publisher","first-page":"e012690","DOI":"10.1136\/bmjopen-2016-012690","volume":"6","author":"KE Mansfield","year":"2016","unstructured":"Mansfield KE, Nitsch D, Smeeth L, Bhaskaran K, Tomlinson LA (2016) Prescription of renin-angiotensin system blockers and risk of acute kidney injury: a population-based cohort study. BMJ Open 6:e012690","journal-title":"BMJ Open"},{"key":"4099_CR26","doi-asserted-by":"publisher","first-page":"e012674","DOI":"10.1136\/bmjopen-2016-012674","volume":"7","author":"P Whiting","year":"2017","unstructured":"Whiting P, Morden A, Tomlinson LA, Caskey F, Blakeman T, Tomson C, Stone T, Richards A, Savovi\u0107 J, Horwood J (2017) What are the risks and benefits of temporarily discontinuing medications to prevent acute kidney injury? A systematic review and meta-analysis. BMJ Open 7:e012674","journal-title":"BMJ Open"},{"key":"4099_CR27","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.kint.2017.07.007","volume":"93","author":"SK Parr","year":"2018","unstructured":"Parr SK, Matheny ME, Abdel-Kader K, Greevy RA Jr, Bian A, Fly J, Chen G, Speroff T, Hung AM, Ikizler TA, Siew ED (2018) Acute kidney injury is a risk factor for subsequent proteinuria. Kidney Int 93:460\u2013469","journal-title":"Kidney Int"},{"key":"4099_CR28","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","volume":"372","author":"JF Mann","year":"2008","unstructured":"Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, Wang X, Maggioni A, Budaj A, Chaithiraphan S, Dickstein K, Keltai M, Mets\u00e4rinne K, Oto A, Parkhomenko A, Piegas LS, Svendsen TL, Teo KK, Yusuf S (2008) ONTARGET investigators: renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 372:547\u2013553","journal-title":"Lancet"},{"key":"4099_CR29","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.2215\/CJN.02850315","volume":"10","author":"Leehey DJ, Zhang JH, Emanuele NV, Whaley-Connell A, Palevsky PM, Reilly RF, Guarino P, Fried LF; VA NEPHRON-D Study Group","year":"2015","unstructured":"Leehey DJ, Zhang JH, Emanuele NV, Whaley-Connell A, Palevsky PM, Reilly RF, Guarino P, Fried LF; VA NEPHRON-D Study Group (2015) BP and renal outcomes in diabetic kidney disease: the veterans affairs nephropathy in diabetes trial. Clin J Am Soc Nephrol 10:2159\u20132169","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4099-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00467-018-4099-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-018-4099-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T05:24:56Z","timestamp":1585891496000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00467-018-4099-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,3]]},"references-count":29,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["4099"],"URL":"https:\/\/doi.org\/10.1007\/s00467-018-4099-8","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734159317.793551425","asserted-by":"object"}]},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,3]]},"assertion":[{"value":"26 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the institutional review board at each center and complied with the Declaration of Helsinki. Written assent was obtained from patients who were old enough to understand and written informed consent was obtained from all of their parents.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"KN received lecture fees from AstraZeneca and Daiichi Sankyo, Co. Ltd. MH received lecture fees from Pfizer Japan Inc. and KYORIN Pharmaceutical Co., Ltd. KI received lecture fees from Daiichi Sankyo, Co., Ltd. and grant from Pfizer Japan Inc. SI received lecture fees from Mylan Inc., AstraZeneca, Pfizer Japan Inc., Shionogi & Co. Ltd., Daiichi Sankyo, Co. Ltd., Meiji Seika Pharma Co., and grant from Pfizer Japan Inc., Merck & Co. YO received consulting fees from Shionogi & Co. Ltd. KI received a grant from Daiichi Sankyo, Co., Ltd., lecture fees and\/or consulting fees from Daiichi Sankyo, Co., Ltd., Takeda Pharmaceutical Co., Ltd., Meiji Seika Pharma Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., NY. The other authors had no disclosure to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}